415 related articles for article (PubMed ID: 33946635)
1. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
Salvaris R; Ong J; Gregory GP
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33946635
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
3. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
González Barca E
Front Immunol; 2022; 13():909008. PubMed ID: 35928819
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
Zinzani PL; Minotti G
J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract][Full Text] [Related]
6. T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma-An Update.
Balendran S; Tam C; Ku M
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959202
[TBL] [Abstract][Full Text] [Related]
7. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Schuster SJ
Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
[TBL] [Abstract][Full Text] [Related]
9. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
10. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.
Cassanello G; Luna de Abia A; Falchi L
Oncoimmunology; 2024; 13(1):2321648. PubMed ID: 38445082
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies in haematological malignancies.
Viardot A; Bargou R
Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
[TBL] [Abstract][Full Text] [Related]
12. The evolving therapy of DLBCL: Bispecific antibodies.
Hutchings M
Hematol Oncol; 2023 Jun; 41(S1):107-111. PubMed ID: 37294965
[TBL] [Abstract][Full Text] [Related]
13. T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions.
Russler-Germain DA; Ghobadi A
Front Oncol; 2023; 13():1168622. PubMed ID: 37465110
[TBL] [Abstract][Full Text] [Related]
14. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
15. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
16. Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma.
Bukhari A; Lee ST
Expert Rev Hematol; 2019 Nov; 12(11):909-918. PubMed ID: 31583919
[No Abstract] [Full Text] [Related]
17. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies.
Al Hadidi S; Heslop HE; Brenner MK; Suzuki M
Mol Ther; 2024 May; ():. PubMed ID: 38822527
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.
Longhitano AP; Slavin MA; Harrison SJ; Teh BW
Blood Rev; 2021 Sep; 49():100810. PubMed ID: 33676765
[TBL] [Abstract][Full Text] [Related]
19. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
